Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 498

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 498
---
 over-allotment option. In addition, the underwriters are entitled to a deferred fee of $0.30 per Unit, or 3.0% of
the gross proceeds of the Initial Public Offering, or $6,900,000 in the aggregate, of which 25.0% will be adjusted net of redemptions
(i.e., for purposes of calculating the deferred underwriting commission net of redemptions, 25.0% of the deferred underwriting commissions
will determined by the dollar amount that is product of (i) 3.0% multiplied by the product of the number of unredeemed public shares,
multiplied by $10.00 and (ii) 25.0%). The deferred fee becomes payable to the underwriters from the amounts held in the Trust Account
solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In addition,
the Company agreed to issue the underwriters 230,000 ordinary shares, denoted as representative shares.

NOTE 7 — SHAREHOLDERS’ DEFICIT

Preference Shares — The
Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other
rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2024, there
were no preference shares issued or outstanding.

Ordinary Shares — The
Company is authorized to issue 220,000,000 ordinary shares with a par value of $0.0001 per share. Holders of ordinary shares are entitled
to one vote for each share. As of December 31, 2024, there are 9,857,143 ordinary shares issued and outstanding, of which an aggregate
of up to 1,285,714 ordinary shares are subject to surrender and forfeiture to the extent that the underwriters’ over-allotment option
is not exercised in full or in part so that the number of Founder Shares will equal 30% of the Company’s issued and outstanding
ordinary shares after the Initial Public Offering (not including the Private Placement Units and the representative shares and assuming
Sponsor does not purchase any Public Shares in the Initial Public Offering). On February 18, 2025 the underwriters exercised their option
to close on the full over-allotment option of 3,000,